NOVEMBER 9, 2015

Cooley and Davis Polk advise Revance Therapeutics on $135 million public offering

Cooley advised Newark-based biopharmaceutical company Revance Therapeutics Inc. in raising $134.6 million in its public offering which closed Nov. 9. The company sold 3,737,500 shares of common stock at a price of $36 per share. The share volume includes the additional allotment of 487,500 shares purchased by the underwriters. Revance develops products used for aesthetic purposes, like treatment for wrinkles, excessive sweating and frown lines.

The Cooley team included Palo Alto-based partners Mark Weeks, Gordon Ho and Mark Windfeld-Hansen and associates Rose Standifer, Sale Kwon and Ryan James. Washington, D.C.-based partner Natasha Leskovsek also worked on the deal.